ADCendo

Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
ADCendo is a biotech start-up company based on a novel cancer drug, invented by the company founders.
The drug is an antibody-drug conjugate (ADC), targeting cancer types that currently cannot be cured.
• Unmet need: Targeted therapy against sarcomas (primary bone cancer and soft tissue tumors), glioblastomas (GBM; the most malignant brain tumors) and certain types of leukemia
• Product: Antibody-drug-conjugate (ADC) against the collagen receptor uPARAP , with proven in vitro efficiency against cell lines of the cancer types mentioned, and convincing in vivo proof of concept in a model of solid cancer.
For sarcomas, no efficient treatment exists if metastasis has occurred. GBM is an extremely aggressive type of cancer and is incurable. For leukemia, some sub-types can be treated but relapse is common, mortality still high and additional treatment options are strongly needed.

Actual status:
• Proof of concept of receptor-specific and potent killing of sarcoma, GBM and leukemic cells has been obtained in vitro
• Very high efficiency and wide window of specificity
• A 100 % cure rate obtained in mice with transplanted human tumor cells, with no adverse effects observed
• Priority-founding patent applications filed
• Commercialization process supported by pre-seed grant from Novo Seeds, Denmark
• Company ADCendo has been founded
• Ideal scientific and clinical network, with founders based in university and hospital positions
• Contact established with key opinion leaders
• Pre-clinical and early clinical development plan in place
Henrik Stage
CEO 
Conference attendance
Niels Behrendt
Section head, D.Sc. the Finsen Laboratory 
Conference attendance

Belvit10

Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Website
www.belvitpharma.ch
Company Profile

Swiss- Israeli based company, fuses the know how of specialists in the pahrmacology and delivery fields with the aim to bring to the market novel drugs based on cannabinoid molecules as stand alone, and synergistic combinations with proper drug delivery technologies

Company Type
Toni Staub
Toni Staub
CEO 
Conference attendance
Biography

Over 30 years of experience in the pharmaceutical world. Also engaged in medical technologies, e.g. maintaining a distribution network for high-end ICU products in Central Europe.
He recognizes the potential of combining highly specialized experts with the current trends, e.g. such as drug delivery for medicinal Cannabis.

Bristol-Myers Squibb

Kristen Bridge
Head of Business Development Strategy and Operations 
Conference attendance
Paul Biondi
Paul Biondi
Senior Vice President, Head of Business Development 
Conference attendance
Biography

Paul Biondi is currently senior vice president, Head of Business Development for Bristol-Myers Squibb responsible for leading the development of strategic partnerships and pursuing external scientific innovations across commercial, development, discovery and technology platforms to complement the company’s internal R&D pipeline.  With deep knowledge of the company’s R&D strategy and portfolio, strong business expertise and understanding of the healthcare landscape, Paul is focused on external innovation that helps Bristol-Myers Squibb develop and deliver transformational medicines for patients with serious diseases.

Prior to this recent appointment, Paul led the R&D Operations organization at Bristol-Myers Squibb for 10 years working for the Head of R&D at BMS and providing strategic insights and operational excellence to enhance the performance of the R&D organization.  As head of R&D Operations he was responsible for optimizing the delivery of the company’s pipeline, managing the company’s R&D portfolio and delivering early- and late-stage clinical operations. He also had responsibility for cross R&D efforts around strategy, analytics, continuous improvement, learning and collaboration. In this role, Paul worked closely with the Business Development leaders in formulating portfolio and disease specific strategies as well as overseeing all integrations of any scientific assets or R&D companies.

Biondi joined Bristol-Myers Squibb in 2002 and was appointed vice president of R&D

Operations when it was formed in May 2005. He was promoted to senior vice president of R&D Operations in 2010.  Paul was appointed senior vice president, Head of Business Development in October 2015.

Biondi holds a bachelor’s degree in government and economics from Dartmouth College and an M.B.A. from J.L. Kellogg School of Management at Northwestern University.

CorAct Advanced Technologies Ltd.

Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15}
Company Website
http://www.cor-act.com/
Company Profile

Cor-Act Advanced Technologies, developing a life supporting system, for patients dying from chronic heart failure). Cor-Act will shortly launch the first fully implantable, Cardiac Assist Device with no blood contact. Our solution is designed as a cost- effective technology to solve the growing gap between of patients waiting for a transplant / mechanical support and the actual expensive available therapies. The Cor-Act’s Cardiac Assist Device system incorporates a miniaturized implantable pump connected to silicone elements which are pressing the myocardium.

Eidit Toren
Eidit Toren
CEO 
Conference attendance

CytoReason

Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15)
Company Website
www.cytoreason.com
Company Profile

CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications

Company Type
Other Sector
Immunology
Keywords

immuno-oncology

inflammatory diseases

inflammatory autoimmune 

big data

biomarker

Year Founded
2016
Pipeline Product 1: Name/Stage
proprietary Cell-Centered Model
Product 1: Description

Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.

The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.  

CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials. 

Investment and Licensing (In/Out) Opportunity 1: Name
collaboration
Dr Orit Shaked
Dr Orit Shaked
BD 
Conference attendance
Biography

Experienced Vice President Of Business Development with a demonstrated history of working in the pharmaceuticals industry. Skilled in Medical Devices, Biotechnology, Fundraising, Biomedical Engineering, and Start-ups. Strong sales professional 

David Harel
President 
Conference attendance

DataHow AG

Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Company Profile

DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.

We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.

DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.

Year Founded
2017
Alessandro Butté
Lecturer and Senior Researcher 
Conference attendance
Fabian Feidl
Co-founder, PhD Candidate ETH 
Conference attendance
Michael Sokolov
Co-founder, COO, Postdoc ETH 
Conference attendance

Di Meliora

Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Volker Hogg
CEO 
Conference attendance

Dicronis

Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Company Website
www.dicronis.com
Company Profile
At Dicronis, we are developing the first DIY lymphatic activity tracker, featuring a microneedles-covered patch and a wearable detector. The microneedles-mediated skin delivery of a fluorescent agent and the measure of its disappearance rate with a coupled wearable device allows for assessment of the dermal lymphatic function. Being minimally-invasive, painless and simple empower it to be used in a home setting by the patient, and accordingly, allow for a much better monitoring on the lymphatic health. This is highly relevant for basic or nutritional research purposes, to evaluate novel therapeutics or as diagnostic biomarker in diseases where this is disrupted, leading to debilitating consequences. For instance, lymphedema, a condition frequently occurring after cancer treatments, outlined by the swelling of a limb. Early diagnosis of the disease is highly crucial to ensure conservative measures, e.g. lymphatic draining massages or compression garments, are employed early-on for best management of the disease. Indeed, current methods of diagnosis of lymphedema are driven, by the clinical manifestation of the symptoms, which delay disease management and therefore worsen the prognosis.
Jovan Jancev
Head of R&D 
Conference attendance
Patrizia Marschalkova
Co-Founder & Project leader at Dicronis 
Conference attendance

Dolopharm Biosciences UG

Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile

Dolopharm is a drug development company from Charité, Berlin, with a focus on GPCR-targeted therapies. Our first pipeline candidate NFEPP for the treatment of severe acute and chronic pain has shown impressive performance in several pre-clinical trial models. In contrast to standard medications, such as opioids, NFEPP avoids drug addiction, respiratory depression, constipation and other known side effects thus representing a potential breakthrough medication for many pain related indications. 

Company Type
Keywords

Drug Development

New Drugs

Pain therapy

Year Founded
2017
Financial Summary

Start-up seeking for initial financing

Pipeline Product 1: Name/Stage
NFEPP/Preclinical
Investment and Licensing (In/Out) Opportunity 1: Name
NFEPP
Opportunity 1: Description

We are currently looking for investors to finance our clinical phase I studies in post-operative pain treatment after knee surgery. So, feel free to talk to us and find out, how to join this outstanding investment opportunity.

Alexander Herrmann
CEO 
Conference attendance

Drooms AG

Company Website
https://www.drooms.com/en
Company Profile

Drooms AG is a leading European provider of secure cloud solutions. This software specialist facilitates highly secure access to confidential documents as well as the ability to safely exchange them with third parties beyond company firewalls. Confidential business processes, such as financing and licensing projects or Board Communication are handled securely, transparently and efficiently with Drooms. Headquartered in Frankfurt, Germany´s banking hub, Drooms is also expanding its global market presence and now has offices  in Munich, London, Paris, Amsterdam, Zug, Madrid, Milan and Vienna. The company is well positioned  to facilitate large-scale local and multi-jurisdictional transactions. Their professional expertise, top-tier reputation and innovative processes have laid the groundwork for a  growing reputation in this market space. Selected References include Astellas, Hormosan, HRA Pharma, Novartis, NovImmune SA and Siemens.

Miriam Muendnich
Press officer DACH 
Conference attendance
Luisa Jacinto Fragata
Luisa Jacinto Fragata
Senior Business Development Manager 
Conference attendance